Humacyte (HUMA) Other financing activities (2020 - 2026)
Humacyte (HUMA) posted quarterly Other financing activities of $5000.0 for Q4 2025, down 97.8% year-over-year from $227000.0 in Q4 2024, and down 91.07% quarter-over-quarter from $56000.0 in Q1 2025.
Humacyte (HUMA) Other financing activities (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Other financing activities for 6 consecutive years, with $5000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Other financing activities fell 97.8% year-over-year to $5000.0; the TTM figure through Mar 2026 stood at $5000.0 (down 99.68% YoY), while the FY2025 annual figure was $61000.0, down 95.96% from the prior year.
- Other financing activities eased to $5000.0 in Q4 2025 per HUMA's latest filing, from $56000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $787000.0 in Q2 2024 and bottomed at $1000.0 in Q1 2022.
- Historically, Other financing activities has averaged $181722.2 across 5 years, with a median of $109000.0 in 2023.
- Annual changes were most pronounced in 2021 — Other financing activities plunged 99.94% — and 2022, when it surged 15200.0%.
- Humacyte's Other financing activities stood at $2000.0 in 2021, then soared by 15200.0% to $306000.0 in 2022, then fell by 17.32% to $253000.0 in 2023, then dropped by 10.28% to $227000.0 in 2024, then plunged by 97.8% to $5000.0 in 2025.
- Business Quant data shows HUMA's Other financing activities at $5000.0 in Q4 2025, $56000.0 in Q1 2025, and $227000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Humacyte | 158.12 Mn | 158.12 Mn | -825,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30,000.00 |
| Jun 30, 2026 | 30,000.00 |
| Dec 31, 2025 | 5,000.00 |
| Dec 31, 2025 | 5,000.00 |
| Mar 31, 2025 | 56,000.00 |
| Mar 31, 2025 | 56,000.00 |
| Dec 31, 2024 | 227,000.00 |
| Dec 31, 2024 | 227,000.00 |
| Sep 30, 2024 | 495,000.00 |
| Sep 30, 2024 | 495,000.00 |
| Jun 30, 2024 | 787,000.00 |
| Jun 30, 2024 | 787,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Dec 31, 2023 | 253,000.00 |
| Dec 31, 2023 | 253,000.00 |
| Sep 30, 2023 | 99,000.00 |
| Sep 30, 2023 | 99,000.00 |
| Jun 30, 2023 | 95,000.00 |
| Jun 30, 2023 | 95,000.00 |